HIV Testing — CPB 0542 | AETNA Coverage Update

Aetna modified CPB 0542 for HIV testing, effective November 27, 2025. Here's what billing teams need to know about the updated coverage criteria and affected codes.

Aetna, a CVS Health company, updated its HIV testing coverage policy under CPB 0542 in Aetna's clinical policy bulletin system. The change refines medical necessity criteria for the full HIV testing algorithm — from initial antigen/antibody combination immunoassays through confirmatory nucleic acid testing. Codes affected include CPT 86703, 87389, 87535, 87536, HCPCS G0475, and nine others. If your practice bills HIV screening or diagnostic testing under Aetna, review this update before processing claims against the November 27, 2025 effective date.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	HIV Testing — CPB 0542
Policy Code	CPB 0542
Change Type	Modified
Effective Date	November 27, 2025
Impact Level	Medium
Specialties Affected	Primary care, infectious disease, OB/GYN, urgent care, laboratory/pathology, federally qualified health centers
Key Action	Audit charge capture for CPT 86701–86703, 87534–87536, 87389, 87390, 87391, 86689, 87806, and HCPCS G0432–G0475 to confirm each claim maps to the correct step in the CDC/USPSTF testing algorithm

---

Aetna HIV Testing Coverage Criteria and Medical Necessity Requirements 2025

Aetna's HIV testing coverage policy follows the CDC's recommended testing algorithm closely. Medical necessity is established at each step — this isn't a blanket approval for any HIV-related test code. Your claim needs to reflect where the patient is in that algorithm, or you risk a claim denial.

Step 1 — Initial Screening Immunoassay

Aetna covers initial HIV screening using an FDA-approved antigen/antibody combination immunoassay. This test detects HIV-1 and HIV-2 antibodies plus HIV-1 p24 antigen. HCPCS G0475 (HIV antigen/antibody combination assay, screening) and CPT 87389 (antigen detection by immunoassay for HIV-1 antigen with HIV-1 and HIV-2 antibodies) are the primary codes here. If the initial result is nonreactive, no further testing is required — and no further testing codes should appear on the claim.

Step 2 — Antibody Differentiation Immunoassay

If the initial immunoassay is reactive, Aetna covers follow-up with an FDA-approved antibody differentiation immunoassay. This test distinguishes HIV-1 antibodies from HIV-2 antibodies. CPT 86703 (antibody, HIV-1 and HIV-2, single result) is the relevant code. A reactive result on both the initial assay and the differentiation assay confirms HIV-1 or HIV-2 infection — or HIV antibodies undifferentiated if the assay can't separate them.

Step 3 — Nucleic Acid Testing (NAT)

When the initial antigen/antibody assay is reactive but the differentiation immunoassay comes back nonreactive or indeterminate, Aetna covers an FDA-approved HIV-1 nucleic acid test (NAT). CPT 87534 (direct probe), 87535 (amplified probe), and 87536 (quantification) all apply here depending on the method used. The result interpretation drives the clinical conclusion — reactive NAT with a nonreactive differentiation assay means acute HIV-1 infection. Reactive NAT with an indeterminate differentiation assay confirms HIV-1 infection. Negative NAT with a nonreactive or indeterminate differentiation assay means the initial immunoassay was a false positive.

That last scenario matters for billing. A false-positive initial result that gets worked up through all three steps still generates reimbursement for each covered step — as long as each test was ordered according to the algorithm. Document the clinical rationale at each step.

Rapid Tests and Oral Specimen Testing

Aetna covers the OraQuick Rapid HIV-1 Antibody point-of-care test as an adequate alternative to laboratory blood tests. HCPCS G0435 (rapid antibody test of oral mucosa transudate) and S3645 (HIV-1 antibody testing of oral mucosal transudate) cover oral specimen testing. HCPCS G0432 and G0433 cover EIA and ELISA-based detection methods respectively.

The Orasure oral HIV test kit also meets medical necessity under CPB 0542 for the same indications as standard HIV testing. If you're a federally qualified health center or community health setting using oral collection kits, these codes are your path to reimbursement — bill them correctly and document the indication.

This coverage policy aligns with USPSTF Grade A recommendations for HIV screening in adults ages 15–65, all pregnant women, and higher-risk individuals outside that age range. Those screening encounters map to ICD-10 Z11.4. Prior authorization is not mentioned in CPB 0542 as a requirement for HIV testing — but check your specific plan contract, because some Aetna plan variants layer PA requirements on top of CPB criteria.

---

Aetna HIV Testing Exclusions and Non-Covered Indications

Two home HIV test kits are explicitly not covered under any Aetna plan:

#	Excluded Procedure Copy
1	Confide Home HIV Test (Johnson & Johnson) — withdrawn from the market in 1997, so this is largely a legacy exclusion
2	Home Access HIV Test System — not covered because it doesn't require a physician's prescription

The real issue here is the prescription requirement. Aetna draws a clear line: over-the-counter home HIV tests are excluded. Prescription-required tests — including the OraQuick and Orasure kits — are covered. If a patient submits a claim or you bill for a non-prescription home kit, expect a denial. There's no appeal path on those.

Don't confuse the Home Access HIV Test System with clinical oral fluid tests ordered by a provider. They're different products with different coverage outcomes.

---

Coverage Indications at a Glance

---

Aetna HIV Testing Billing Guidelines and Action Items 2025

1. Map every HIV test code to its algorithm step before November 27, 2025.

The effective date of this updated policy is November 27, 2025. Before then, audit your charge capture templates for all HIV testing codes — CPT 86689, 86701, 86702, 86703, 87389, 87390, 87391, 87534, 87535, 87536, 87806, and HCPCS G0432, G0433, G0435, G0475, S3645. Each code should tie to a specific step in the CDC algorithm. If your EHR order sets or charge capture tools don't reflect the algorithm sequence, fix them now.

2. Use G0475 for initial combination screening — not CPT 86701 or 86702 alone.

G0475 is the HCPCS code specifically for HIV antigen/antibody combination assay screening. Billing 86701 or 86702 individually for a combination screening assay creates a mismatch between the code and the service. Aetna's HIV testing billing guidelines require the correct test to be billed — submitting a single-analyte code for a combination assay is a common audit trigger.

3. Document the reactive/nonreactive/indeterminate result that justifies each subsequent test.

Step 2 (differentiation immunoassay) is only covered when Step 1 is reactive. Step 3 (NAT) is only covered when Step 2 is nonreactive or indeterminate. If your documentation doesn't include those intermediate results, you can't support medical necessity for downstream codes. A claim denial on CPT 87535 or 87536 often traces back to missing documentation of the differentiation assay result.

4. Confirm diagnosis codes match the clinical scenario.

Use Z11.4 for routine screening with no known infection. Use Z20.6 for known or suspected exposure. Use Z21 for asymptomatic HIV-positive patients. Use B20 for HIV disease. Mismatched diagnosis codes — especially billing a confirmed-infection code for a screening encounter — generate denials and compliance exposure. Your billing team should audit ICD-10 pairings against the order reason for every HIV testing claim.

5. Do not bill home HIV test kits.

The Confide Home HIV Test and Home Access HIV Test System are excluded under all Aetna plans. If patients ask about at-home testing coverage, the answer is no — Aetna's coverage policy requires a prescription. If you're a retail clinic or pharmacy-adjacent practice where these products might appear in your charge capture, remove them from Aetna billing workflows entirely.

6. Check plan-level PA requirements separately.

CPB 0542 doesn't list prior authorization as a requirement for HIV testing. But individual Aetna plan contracts can add PA requirements on top of CPB criteria. If your practice treats a high volume of Aetna members across multiple plan types, have your billing team verify PA requirements by plan before the effective date. Your compliance officer can help assess exposure if you're uncertain about your specific plan mix.

---

CPT, HCPCS, and ICD-10 Codes for HIV Testing Under CPB 0542

Covered CPT Codes (When Selection Criteria Are Met)

Covered HCPCS Codes (When Selection Criteria Are Met)

Key ICD-10-CM Diagnosis Codes

---